| Endpoint | IVIG (N=18) | Rituximab-based (N=5) | PE (N=15) | Bortezomib-based (N=30) | Combination with rituximab/bortezomib-based (N=10) | P-value |
|---|---|---|---|---|---|---|
| Pre-treatment cPRA | 54.5 ± 36.2 | 87.8 ± 17.5 | 63.9 ± 34.3 | 87.5 ± 11.7 | 89.5 ± 9.3 | <0.001 |
| Post-treatment cPRA | 70.7 ± 31.8 | 75.8 ± 14.7 | 71.3 ± 34.1 | 79.0 ± 22.8 | 87.2 ± 8.5 | 0.516 |
| Change in cPRA Post-treatment | 12.9 ± 24.1 | -12.0 ± 12.9 | 6.0 ± 43.4 | -8.5 ± 19.8 | -2.3 ± 6.2 | 0.060 |
| Change in Class I Antibodies | -1718 ± 3652 | -4338 ± 2513 | -4059 ± 4496 | -3451 ± 3435 | -1958 ± 1976 | 0.394 |
| Change in Class II Antibodies | 213 ± 2944 | -2187 ± 3093 | 626 ± 5243 | -856 ± 3072 | -913 ± 1608 | 0.730 |
| Overall Change in Antibodies (Class I and Class II) | -522 ± 3011 | -3339 ± 2803 | -2392 ± 5706 | -1830 ± 3412 | -1428 ± 1861 | 0.527 |